You signed in with another tab or window. Reload to refresh your session.You signed out in another tab or window. Reload to refresh your session.You switched accounts on another tab or window. Reload to refresh your session.Dismiss alert
Based on discussions with MOH Clinical Committee and ARGO CMD Working Group, a new term "Biochemical progression" will be added to the relapse_type field in the Follow Up schema for prostate cancer. This will require a validation check that permits anatomic_site_progression_or_recurrence field to not be submitted because biochemical progression is not related to a specific site and is a (blood) test done to assess disease status in prostate cancer
The text was updated successfully, but these errors were encountered:
Implementation:
Based on discussions with MOH Clinical Committee and ARGO CMD Working Group, a new term "Biochemical progression" will be added to the
relapse_type
field in the Follow Up schema for prostate cancer. This will require a validation check that permitsanatomic_site_progression_or_recurrence
field to not be submitted because biochemical progression is not related to a specific site and is a (blood) test done to assess disease status in prostate cancerThe text was updated successfully, but these errors were encountered: